Eli Lilly & Co. has hit the ground running with a carefully crafted pitch to differentiate its third-to-market CGRP inhibitor Emgality (galcanezumab-gnlm), which the US FDA has now approved in a 120 mg monthly dose for the preventative treatment of migraine in adults.
The company revealed the approval late in the evening of Sept. 27 and immediately began making its pitch to gain patient, physician and payer preference in the newly competitive migraine market in which Amgen Inc.'s and Novartis AG's Aimovig (erenumab) was the first approved CGRP inhibitor in May followed by Teva Pharmaceutical Industries Ltd.'s Ajovy (fremanezumab) on Sept. 14
